Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 30, 2013	Mar. 31, 2012
Cash Flows From Operating Activities
Net income (loss)	$ 1,468,525	$ (4,431,853)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation of leasehold improvements and equipment	79,184	85,422
Amortization of intangibles	4,964	3,391
Share-based compensation expense	351,590	65,987
Gain on sale of assets	(2,891,917)
Loss from disposal of equipment		1,879
Interest added to note receivable	(680)
Changes in operating assets and liabilities:
Trade receivables	971,153	(676,991)
Inventories	164,322	(1,145,295)
Prepaid expenses and other assets	(86,181)	519,481
Accounts payable	(683,152)	816,215
Accrued expenses	(72,190)	101,229
Customer deposits and other	4,201	20,109
Deferred rent	(15,621)	(15,811)
Net cash used in operating activities	(705,802)	(4,656,237)
Cash Flows From Investing Activities
Purchases of leasehold improvements and equipment	(7,428)	(4,714)
Purchase of intangible assets	(40,000)	(2,000)
Proceeds from sale of assets	500,000
Net cash provided by (used in) investing activities	452,572	(6,714)
Cash Flows From Financing Activities
Proceeds from issuance of common stock, net of issuance costs		10,070,238
Proceeds from exercise of stock options	6,769
Proceeds from exercise of warrants	716,999
Principal payments on capital leases	(23,962)	(22,260)
Net cash provided by financing activities	699,806	10,047,978
Net increase in cash	446,576	5,385,027
Cash Beginning of Period	520,000	420,152
Cash Ending of Period	966,576	5,805,179
Supplemental Disclosures of Cash Flow Information
Cash payments for interest	7,791	8,264
Supplemental Schedule of Noncash Investing Activity
Capital lease obligation incurred for the purchase of equipment	116,122	50,786
Supplemental Schedule of Noncash Share-based Compensation
Stock awards issued for services prior to the period	14,560
Changes in stock and warrant awards issued for future services	182,502
Supplemental Schedule of Noncash Activities Related to Sale of BlueScience Consumer Product Line
Assets transferred	3,526,677
Liabilities transferred	368,873
Consideration received, net of $500,000 cash proceeds	$ 5,549,721